Diallyl sulfide

Diallyl Sulfide (DAS): A Comprehensive Reference

1. Identity: Chemical Name, Structure, and Physical Properties

Diallyl sulfide (abbreviated DAS) is an organosulfur compound with the molecular formula C₆H₁₀S and the PubChem Compound Identifier (CID) 11617. DAS belongs to the class of organosulfur compounds known as dialkylthioethers, containing a thioether group that is substituted by two allyl (2-propenyl) groups. Its systematic IUPAC name is di-2-propenyl sulfide, and it is also listed in the literature under the synonyms allyl sulfide, diallyl monosulfide, and 2,2'-thiobis(1-propene).

Diallyl sulfide (C₆H₁₀S, DAS) is one of the novel natural organosulfur compounds, which is mostly obtained from the genus Allium plants. DAS is a flavor component of garlic that undergoes metabolism, resulting in the formation of various compounds through S-oxidation and subsequent glutathione conjugation.

Within the broader family of garlic organosulfur compounds, DAS is the simplest member of the diallyl polysulfide series, which also includes diallyl disulfide (DADS, C₆H₁₀S₂) and diallyl trisulfide (DATS, C₆H₁₀S₃). Diallyl sulfides such as DAS, DADS, and DATS are lipophilic thioesters derived from the natural precursor allicin when garlic cloves are crushed.

2. Natural Source and Botanical Context

DAS is primarily derived from Allium sativum L. (garlic), a bulbous flowering plant belonging to the genus Allium within the family Amaryllidaceae (formerly placed in Liliaceae). Garlic (Allium sativum) is a species of bulbous flowering plants in the genus Allium; its close relatives include the onion, shallot, leek, chives, Welsh onion, and Chinese onion, and it is native to Central Asia, northeastern Iran, and the foothills of the Himalayas.

Garlic is constituted of water, fiber, carbohydrates, proteins, fat, and 33 sulfur-containing compounds. Cutting or crushing of a garlic clove causes allinase-mediated conversion of S-allylcysteine sulfoxide (alliin) to allicin; decomposition of allicin yields diallyl sulfide (DAS), diallyl disulfide (DADS), and related compounds. More precisely, allinase converts alliin to allicin with pyruvate and ammonium ion as by-products of this reaction; self-condensation of sulfenic acid molecules formed in this reaction yields allicin, and this unstable allicin is then transformed into lipophilic polysulfides such as DAS, DADS, and DATS.

DAS is found in significant quantities in garlic essential oil. Steam distillation of garlic bulbs yields garlic oil, with allyl polysulfides being the most abundant compounds present, accounting for nearly 94% of the total amount, with approximately 4.7–8% being diallyl sulfide (DAS) and 21.9–40% diallyl disulfide (DADS). Gas chromatographic analyses have confirmed this distribution: garlic essential oil has been found to contain major compounds including diallyl sulfide (8.6%), diallyl disulfide (28.36%), dimethyl tetrasulfide (15.26%), trisulfide di-2-propenyl (10.41%), and tetrasulfide di-2-propenyl (9.67%).

DAS is also a constituent of other Allium species. DAS is a dominant constituent of allyl derivatives found in garlic oils, and this molecule, along with other allyl derivatives such as diallyl disulfide (DADS) and diallyl trisulfide (DATS), exhibits pharmacological and biological activities including anti-inflammatory, anticarcinogenic, and antiangiogenic effects.

3. Common Forms and Preparations

The profile of DAS and related organosulfur compounds in a garlic-based preparation is highly dependent on the processing method. The availability of organosulfur compounds varies in different garlic preparations; in garlic homogenate, the main constituents include allicin and related thiosulfinates, while other processing methods yield different profiles.

Sulfur compounds that exhibit higher stability, such as DAS, DADS, and DATS, are more effectively maintained in garlic powder compared to allicin, which is extremely labile. In recent years, global demand for medicinal or functional garlic has surged, introducing several products such as garlic oil, aged garlic, black garlic, and inulin into the market. DAS, DADS, triallyl trisulfide, phenolics, flavonoids, and others are among the most commercially recognized active ingredients in garlic and its products.

The major commercial and research preparations in which DAS occurs include:

• Garlic essential oil (steam-distilled): The preparation richest in DAS, DADS, and DATS, produced by steam distillation of garlic bulbs.
• Garlic oil capsules: Soft-gel capsules containing diluted garlic oil in a vegetable oil carrier. The taste and odor of DADS and other constituents of garlic oil significantly limit the concentration of active ingredients, as the garlic oil is typically heavily diluted — e.g., the capsules often contain over 99% vegetable oil.
• Garlic powder (dehydrated): Produced by drying and grinding garlic; DAS and related stable sulfides are retained but allicin content depends on processing conditions.
• Aged garlic extract (AGE): Prepared by prolonged aging of garlic in aqueous ethanol; the process converts allicin derivatives primarily into stable water-soluble compounds such as S-allylcysteine (SAC), with lower concentrations of DAS.
• Isolated/purified DAS: Used in research settings as a chemically defined substance; commercially available as a laboratory reagent (≥97% purity) for in vitro and in vivo experimental use.

The bioavailability of these compounds in garlic powder is affected by factors such as processing methods and storage conditions. Specific preparation methods, such as fermentation and aging, contribute to the therapeutic versatility of garlic, as observed in black garlic traditions.

4. Traditional and Historical Use

Although DAS as an isolated chemical entity was not identified until the modern era of analytical chemistry, it is one of the principal volatile constituents responsible for the pharmacological properties attributed historically to garlic. Garlic (Allium sativum) has been integral to human culture and medicine for more than 5,000 years, serving as both a culinary staple and therapeutic agent; its ethnobotanical and medicinal significance spans civilizations from its origins in Central Asia to its global dissemination through trade and cultural exchange.

4.1 Ancient Egypt

In the Ebers papyrus (around 1500 BC), various medicinal plants were mentioned, and among others the much-appreciated garlic, described as efficient in healing 32 illnesses. Garlic was used as a food and sacred offering, consumed by pyramid builders to enhance strength and endurance, and used in rituals to symbolize protection and vitality. The youngest pharaoh Tutankhamun (1320 BC) was sent on his journey to life beyond the grave accompanied by garlic as a patron of his soul; archaeologists have discovered garlic bulbs in the pyramids.

4.2 Ancient China

The use of garlic as a food and as a medicinal agent has ancient origins in Asia; the best estimate is that by or before 2000 BC, garlic was in wide use in China and formed part of the daily diet, particularly when consumed together with raw meat. In ancient Chinese medicine, garlic was prescribed to aid respiration and digestion, most importantly diarrhea and worm infestation. Fatigue, headache, and insomnia were often treated with garlic; there are also indications that garlic was used to treat and improve male potency.

4.3 Ancient India (Ayurveda)

In ancient Indian medicine, garlic was a valuable remedy used as a tonic, roborans, to cure a lack of appetite, common weakness, cough, skin disease, rheumatism, and haemorrhoids; in the Vedas — the Indian holy book — garlic was mentioned among other medicinal plants.

4.4 Greek, Roman, and Other Classical Cultures

Ancient cultures, including those of Egypt, Greece, China, Persia, Sumer, and India, recognized garlic's antimicrobial, cardiovascular, and immune-enhancing properties, integrating it into diets, rituals, and medicinal practices. There is evidence that athletes were given garlic to enhance strength during the first Olympics in Greece.

4.5 Epidemic Medicine

In the past, garlic was utilized as a remedy during various epidemics such as typhus, dysentery, cholera, and influenza; whenever an epidemic emerged, garlic was among the first preventive and curative remedies employed.

It is important to note that in all of these traditions, garlic was used as a whole food or a crude preparation (fresh bulb, decoction, tincture, topical poultice). The specific contribution of DAS versus allicin, DADS, DATS, or other co-occurring compounds was entirely unknown to ancient practitioners; the identification of DAS as a discrete molecule and its pharmacological study belongs entirely to the modern scientific era.

5. Key Constituents and Chemistry of DAS

Within the garlic organosulfur chemical family, DAS is the monosulfide member and is structurally the simplest. Bioactive garlic constituents, including allicin, diallyl sulfide/disulfide/trisulfide, ajoene, and S-allyl-cysteine, demonstrate antioxidant, anti-inflammatory, antithrombotic, antineoplastic, antimicrobial, and neuroprotective properties.

DAS is metabolized in vivo primarily by the cytochrome P450 enzyme CYP2E1. DAS is sequentially converted to diallyl sulfoxide (DASO) and diallyl sulfone (DASO₂) by cytochrome P450 2E1 (CYP2E1). In addition to being a competitive inhibitor of CYP2E1 in vitro, DAS is known to cause irreversible inhibition of CYP2E1 in rats in vivo; this latter property is believed to be mediated by the DAS metabolite diallyl sulfone (DASO₂), which is thought to be a mechanism-based inhibitor of CYP2E1.

The central sulfur atom in the DAS structure interacts with the heme of the CYP2E1 active site, thereby acting as an inhibitor; however, DAS is also metabolized at the same position, resulting in the production of toxic sulfur metabolites such as diallyl sulfoxide and diallyl sulfone.

The metabolic fate of DAS also involves glutathione (GSH) conjugation pathways. Studies were carried out to detect and identify potential glutathione (GSH) conjugates of DAS and its metabolites; experiments conducted in vitro showed that GSH reacted spontaneously with DASO to form conjugates M9 and M10, and with DASO₂ to form M10.

6. Established Mechanisms of Action

6.1 Inhibition of Cytochrome P450 2E1 (CYP2E1)

The most thoroughly characterized mechanism of DAS is its selective inhibition of CYP2E1. DAS is a selective inhibitor of cytochrome P450 2E1 (CYP2E1), which is known to metabolize many xenobiotics including alcohol and analgesic drugs in the liver. DAS, DASO, and DASO₂ are competitive inhibitors of CYP2E1; DASO₂, in addition, is a suicide inhibitor of CYP2E1. CYP2E1-mediated alcohol/drug metabolism produces reactive oxygen species and reactive metabolites, which damage DNA, protein, and lipid membranes, subsequently causing liver damage. By inhibiting this enzyme, DAS can reduce such hepatotoxic cascades.

The importance of CYP2E1 in toxicology and carcinogenesis is well-established. Altered expression and/or activity of CYP2E1 has been implicated in carcinogenesis; in particular, genetic predisposition via inheritance of specific CYP2E1 polymorphisms or overexpression of CYP2E1 mRNA have been observed in clinical samples, and CYP2E1-mediated metabolism has also been implicated in generating carcinogenic DNA adducts.

6.2 Antioxidant Effects and Nrf2 Pathway Activation

DAS modulates the master antioxidant transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2). The major cellular changes associated with protective effects of DAS include increased expression of antioxidant enzymes (AOEs) and glutathione levels, and reduced activation of proinflammatory signaling molecules like NF-κB and COX-2; enhanced nuclear translocation of transcription factor Nrf2 has been identified as an important event responsible for the antioxidant effects observed with DAS.

Studies indicate that diallyl sulfides can activate drug-metabolizing enzymes such as NQO1 and HO-1 in a manner that depends on the Nrf2/ARE pathway.

6.3 Anti-inflammatory Mechanisms

DAS has antioxidant and anti-inflammatory activities; the compound inhibits inflammatory signaling mediated by NF-κB and STAT3. Diallyl sulfide can impede oxidative stress and chronic inflammation as suggested by the literature. These anti-inflammatory properties are relevant to multiple organ systems and disease processes.

6.4 Pro-apoptotic and Cell Cycle Effects

DAS-mediated significant increase in the levels of pro-apoptotic protein (Bax) and p53-mediated cell cycle arrest have been identified as alternate pathways activating apoptosis. The chemopreventive effects of DAS have been attributed to its inhibitory effects on CYP2E1-mediated bioactivation of carcinogenic chemicals.

6.5 Phase II Enzyme Induction

Beyond CYP2E1 inhibition, DAS influences the broader xenobiotic-metabolizing enzyme system. DAS has been shown to induce other CYP and phase II enzymes as well as decrease hepatic catalase activity. Induction of phase II detoxification enzymes (such as glutathione S-transferase) contributes to DAS's chemoprotective profile by facilitating the conjugation and elimination of electrophilic carcinogens.

6.6 Immunomodulatory Activity

DAS has proved to be anticancer, antimicrobial, anti-angiogenic, and immunomodulatory in function as demonstrated by multiple investigations. The mechanisms underlying immunomodulation are thought to involve modulation of cytokine signaling, though these are less completely characterized than the CYP2E1 and Nrf2 pathways at present.

7. Scientific Evidence by Health Area

7.1 Cancer Chemoprevention

Cancer chemoprevention is the area with the most extensive preclinical literature for DAS. Garlic-derived allyl sulfides are well-known for their anti-cancer properties; among allyl sulfides, DAS has been extensively studied for its putative role in anticancer properties.

Animal and in vitro evidence: DAS, DASO, and DASO₂ have been shown to reduce the incidence of a multitude of chemically induced tumors in animal models; the impediment of phase I activation of carcinogens is hypothesized to be accountable for the reduction in tumor incidence. These compounds have been shown to reduce carbon tetrachloride-, N-nitrosodimethylamine-, and acetaminophen-induced toxicity in rodents; all three chemicals are substrates for CYP2E1.

In colon cancer models, in colon epithelial cells, DAS has been reported to inhibit carcinogen-mediated nuclear damage. Allyl sulfides have been shown to inhibit invasion and metastasis in colon cancer cells, with DATS being more effective than DADS and DAS at concentrations of 10 and 25 μM.

In breast cancer cell line models, DAS is a garlic organosulfide that has been shown to inhibit both the initiation and promotion phases of cancer in vivo and in vitro, as well as reduce the risk of cancer in epidemiological studies. Most importantly, DAS has been shown to inhibit DES-induced formation of DNA adducts (in vivo) in the breast tissue of ACI rats.

In a mouse skin carcinogenesis model, DAS, a major flavour component of garlic, is known to modulate xenobiotic metabolism and possess antitoxic, bactericidal, antineoplastic, hypolipidemic, and hypocholesterolemic effects.

Lung tumorigenesis was also studied: DAS and DASO₂ inhibited the bioactivation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and related lung tumorigenesis in mice.

Important limitation: All of these effects are observed at concentrations much higher than what is normally ingested by humans; the biological activities of garlic and its related compounds at lower concentrations that mimic human consumption remain to be studied further. There are no published randomized controlled clinical trials in humans assessing DAS as an isolated compound for cancer prevention or treatment. The evidence base is predominantly preclinical (in vitro cell culture and animal model), and clinical translation has not been established.

7.2 Hepatoprotection (Liver Protection)

DAS has been intensively studied as a hepatoprotective agent, particularly against chemical- and drug-induced liver injury. DAS, an organosulfur compound extracted from garlic, has been investigated for its effects on drug-induced or chemical-induced liver injury caused by acetaminophen (APAP) or carbon tetrachloride (CCl₄) in mice.

In a mouse study, DAS (100, 200, or 400 μmol/kg) was orally administered 1 hour before APAP or CCl₄ intraperitoneal injection; serum aminotransferase activities and liver histopathological examination showed that DAS exhibited obvious hepatoprotective effects against acute liver injury induced by APAP or CCl₄.

The mechanism of hepatoprotection is primarily attributed to CYP2E1 inhibition. CYP2E1 is involved in the metabolism of more than 85 xenobiotics; DAS, a selective inhibitor of CYP2E1, has shown protective effects against alcohol- and acetaminophen-induced hepatotoxicity in many studies. DAS can rescue the system from deleterious effects by inhibiting CYP2E1 metabolism most likely using competitive and/or mechanism-based inhibition.

Human evidence: One small human pharmacokinetic study (Loizou et al., 2001, Human & Experimental Toxicology) directly examined CYP2E1 inhibition by DAS in volunteers. The effects of acute administration of dietary levels of ethanol and the garlic oil extract DAS on CYP2E1 activity in volunteers were studied using the selective probe substrate chlorzoxazone (CZX); the ratio of the CZX metabolite 6-hydroxychlorzoxazone (6-OHCZX) to CZX was taken to indicate CYP2E1 activity; the mean differences between baseline and DAS-treated (0.2 mg/kg) CYP2E1 activities were significantly different (two-tailed p value = 0.0242, n = 8); likewise, the mean differences between baseline and ethanol-treated (0.8 g/kg) CYP2E1 activities were also significantly different (p = 0.0005, n = 7); and the reduction in in vivo CYP2E1 activity by DAS was consistent with reported inhibition observed in vitro. This constitutes direct human evidence for CYP2E1 inhibition, though the study was small (n = 8) and assessed only a pharmacological endpoint, not a clinical liver disease outcome.

7.3 Cardiovascular Effects

Studies have explored that DAS could thwart the development of chronic diseases like cancer, neuronal, and cardiovascular disease through modulating mechanistic pathways involved in pathogenesis. DAS's cardiovascular-relevant activities include antioxidant action, anti-inflammatory signaling suppression, and inhibition of lipid peroxidation.

In a mouse model of dilated cardiomyopathy, research has reported that DAS protects against disease progression via inhibition of oxidative stress and apoptosis (published in Molecular Medicine Reports, 2021). The evidence for cardiovascular effects of DAS in particular (as opposed to garlic extracts generally, or DADS/DATS specifically) remains predominantly preclinical. No clinical trials specifically isolating DAS as the agent of cardiovascular benefit in humans have been identified in the literature.

7.4 Neuroprotection

Neuroprotective effects of DAS against transient cerebral ischemia were observed in an in vivo study; in rats subjected to focal cerebral ischemia for 2 hours followed by reperfusion for 24 hours, DAS pretreatment for 7 days before ischemia/reperfusion significantly lowered the infarct volume compared to non-treated rats; furthermore, a decrease in the number of TUNEL-positive cells was observed in DAS-pretreated rats, suggesting reduced apoptosis following DAS treatment; immunohistochemistry and Western blot analysis revealed a decrease in caspase-3 expression, a hallmark for ischemic cell apoptosis, and an increase in anti-apoptotic Bcl-2 expression in DAS-pretreated ischemia/reperfusion-induced rats compared to control animals.

Organosulfur compounds in garlic are responsible for biological functions such as antioxidant and anti-inflammatory activity, which can be attributed to their chemical structure and function as neuroprotective agents. The available neuroprotection evidence for DAS specifically is entirely from animal models and has not been tested in human clinical trials.

7.5 Antimicrobial and Antifungal Activity

DAS has proved to be anticancer, antimicrobial, anti-angiogenic, and immunomodulatory in function as demonstrated by multiple investigations. DAS and related diallyl sulfides contribute to garlic's known bactericidal and antifungal properties.

GC-MS analysis of garlic essential oil revealed major constituents including diallyl trisulfide (39.79%), diallyl disulfide (32.91%), and diallyl sulfide (7.02%), all of which contribute to its antimicrobial spectrum. In antifungal studies on wood-decay fungi, diallyl trisulfide was the most effective against tested fungi at IC₅₀ values of 56.1 and 31.6 μg/mL, respectively, with DAS and DADS also demonstrating activity. Among the diallyl sulfides, DATS appears more potent than DADS and DAS in most antimicrobial models.

The antimicrobial evidence for isolated DAS in humans is absent; existing data are in vitro or in animal models.

7.6 Nephroprotection

DAS has been studied in a Wistar rat model for nephrotoxicity protection. Research published in the literature described that diallyl sulfide enhances antioxidants and inhibits inflammation through the activation of Nrf2 against gentamicin-induced nephrotoxicity in Wistar rats. Again, this is preclinical evidence; no human clinical data for renal protection by isolated DAS exist.

7.7 Anti-angiogenic Effects

DAS has proved to have anti-angiogenic function as demonstrated by multiple investigations. Anti-angiogenic mechanisms — relevant to tumor suppression — have been observed in preclinical models but have not been evaluated in human clinical studies.

8. Overall Assessment of Evidence Strength

The following table summarizes the current state of evidence for DAS across health areas:

• Cancer chemoprevention: Extensive in vitro and animal evidence; no human clinical trials. Evidence is preliminary and preclinical only. Concentration-dependent effects observed in animal models may not translate to physiologically achievable human doses.
• Hepatoprotection via CYP2E1 inhibition: Strong mechanistic and animal evidence; one small human pharmacological study (n = 8) confirming CYP2E1 inhibition in vivo at 0.2 mg/kg DAS. Clinical hepatoprotection outcomes in humans not demonstrated.
• Cardiovascular protection: Preclinical animal models only; no human clinical trials for DAS specifically.
• Neuroprotection: Animal (rodent ischemia) models only; no human clinical data.
• Antimicrobial/antifungal: In vitro and animal models; no human trials for DAS as an isolated agent.
• Nephroprotection: Rodent models only; no human clinical data.

The overall scientific literature summarizes current advances in the field of DAS including its anticancer properties, role as a CYP2E1 inhibitor, and potential as a preventing agent of cellular toxicities from alcohol, analgesic drugs, and xenobiotics, as well as from diseases like HIV and diabetes — but the overwhelming majority of this evidence derives from in vitro and animal studies, and human clinical trials remain largely absent.

9. Dosage Forms and Dosages Reported in Studies

Because no standardized therapeutic dosage has been established for DAS in humans, the following dosages are reported solely as they appear in specific research publications:

• Human pharmacological study (CYP2E1 inhibition): The mean differences between the baseline and DAS-treated (0.2 mg/kg) CYP2E1 activities were significantly different (two-tailed p value = 0.0242, n = 8). This was the dose used by Loizou et al. (2001) in the only identified human study specifically using DAS.
• Mouse hepatoprotection study: DAS (100, 200, or 400 μmol/kg) was orally administered 1 hour before APAP or CCl₄ intraperitoneal injection, and serum and liver tissue were collected 24 hours after exposure.
• Mouse ischemia/reperfusion neuroprotection study: In rats subjected to focal cerebral ischemia for 2 hours followed by reperfusion for 24 hours, DAS pretreatment for 7 days before ischemia/reperfusion significantly lowered the infarct volume compared to non-treated rats. (The exact dose used in this study was not fully extracted from available text.)
• Acute toxicity study (mice): DAS was administered intraperitoneally to C57BL/6 mice at a range of concentrations (160, 1280, 1600, and 1920 mg/kg).

In recent years, global demand for medicinal or functional garlic has surged, introducing several products such as garlic oil, aged garlic, black garlic, and inulin into the market, but standardized DAS content in commercial supplement preparations is not routinely reported, and a comparison of garlic oil dietary supplements found a 50-to-1 range in their total content of allyl sulfides.

10. Safety Considerations and Drug Interactions

10.1 Acute Toxicity

DAS is a garlic-derived organosulfur compound known for its chemotherapeutic properties, as a strong food additive and a potential radiomitigator; despite its therapeutic potentials, the apparent lack of toxicity data has historically hindered its clinical applications; a study investigated the pre-clinical toxicity of DAS to identify the maximum tolerable and lethal doses and to understand its underlying mechanisms at toxic doses. A single dose of DAS up to 1280 mg/kg was well-tolerated in mice without significant changes in standard toxicological parameters. Toxicity was observed at higher intraperitoneal doses (1600–1920 mg/kg) in that same mouse study, representing concentrations far beyond any plausible human dietary exposure.

10.2 Cytotoxicity from Metabolites

DAS presents a dual profile in which it is itself a CYP2E1 substrate whose metabolism generates potentially toxic products. DAS, a selective inhibitor of CYP2E1, has shown protective effects against alcohol- and acetaminophen-induced hepatotoxicity in many studies; however, DAS is also a CYP2E1 substrate that on metabolism produces toxic metabolites and causes cytotoxicity. DAS also causes toxicity at relatively high dosages and with long exposure times. This duality — protectant at low doses, potentially cytotoxic at high doses — is an important consideration in any therapeutic evaluation.

10.3 Allergic Reactions

DAS has shown appreciable allergic reactions and toxicity, as it can also affect normal cells; thus its use in the prevention and treatment of cancer is limited. Garlic allergy and contact dermatitis associated with garlic compounds (including diallyl sulfides) are documented in the dermatological literature. These reactions have been most frequently associated with topical garlic exposure.

10.4 CYP2E1-Related Drug Interactions

The most pharmacologically significant interaction involves DAS's inhibition of CYP2E1. One of the active constituents in garlic, diallyl sulfide, is a potent inhibitor of the phase I enzyme CYP2E1; CYP2E1 is involved in the metabolic activation of several environmental and dietary carcinogens, such as nitrosamines. Because CYP2E1 metabolizes numerous drugs and endogenous substrates, inhibition by DAS could theoretically alter the metabolism of any CYP2E1-dependent substrate — including acetaminophen (paracetamol), ethanol, chlorzoxazone, and certain volatile anesthetics. This interaction has been confirmed in at least one human study (Loizou et al., 2001).

Additionally, DAS, a compound found in garlic, has been shown to inhibit CYP2E1. Although DAS does not appear to have major effects on CYP2D6 or CYP1A2, as there is no effect of garlic oil on the activity of CYP2D6, the bioavailability of debrisoquine and dextromethorphan is not altered; moreover, as CYP1A2 activity is not altered by garlic, there was a significant effect noted on the bioavailability of caffeine.

10.5 Interaction with Anticoagulants

Garlic and its organosulfur constituents, including DAS, have been associated with platelet inhibition and potential interactions with anticoagulant therapy. DAS, a compound found in garlic, has been shown to inhibit CYP2E1, which is one mechanistic pathway through which garlic preparations may interact with drugs metabolized by this enzyme. The broader garlic-warfarin interaction is documented; however, the specific contribution of DAS (as opposed to other garlic constituents such as ajoene, which has direct antiplatelet activity) to this interaction has not been definitively quantified in clinical studies.

10.6 Dose-Concentration Considerations

A consistently noted limitation in safety assessment is the issue of dose translation from preclinical studies to human exposure. All of these effects are observed at concentrations much higher than what is normally ingested by humans; the biological activities of garlic and its related compounds at lower concentrations that mimic human consumption remain to be studied further. This is critical context for interpreting both the efficacy and safety data for DAS.

11. Body Systems Associated with DAS Activity

Based on the peer-reviewed literature, DAS has been studied in relation to the following body systems:

• Hepatic (liver): CYP2E1-mediated hepatoprotection against xenobiotic-induced injury; modulation of phase I and phase II detoxification enzyme expression.
• Oncological (multiple cancer types): Chemoprevention in models of colon, breast, skin, lung, and other cancers via CYP2E1 inhibition, Nrf2 activation, apoptosis induction, and cell cycle arrest.
• Neurological: Neuroprotection in ischemia/reperfusion animal models via anti-apoptotic signaling (Bcl-2 upregulation, caspase-3 downregulation).
• Cardiovascular: Antioxidant and anti-apoptotic effects studied in cardiomyopathy models; DAS could thwart the development of chronic diseases like cancer, neuronal, and cardiovascular disease through modulating mechanistic pathways involved in pathogenesis.
• Renal: Protection against gentamicin-induced nephrotoxicity in rodent models via Nrf2 pathway.
• Immune system: Immunomodulatory activity documented in multiple investigations, though mechanisms are less characterized than antioxidant or CYP2E1 pathways.
• Gastrointestinal: Anti-inflammatory effects in DSS-induced colitis animal models; this small-molecule compound was also effective after oral administration for attenuating DSS-induced colitis in mice.
• Microbial defense: Broad-spectrum antimicrobial and antifungal activity demonstrated in vitro.

References

• PubChem. Diallyl Sulfide | C6H10S | CID 11617. National Library of Medicine.
• Rao PS, Midde NM, Miller DD, et al. Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1. Curr Drug Metab. 2015;16(6):486–503. PMC4663692.
• Loizou GD, et al. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol. 2001;20(7):321–7.
• Yang CS, Chhabra SK, Hong JY, Smith TJ. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr. 2001;131(3s):1041S–1045S.
• Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. PubMed. PMID: 9084912.
• Diallyl sulfide inhibits diethylstilbestrol induced DNA damage in human breast epithelial cells (MCF-10A). PMC4426958.
• Diallyl sulfide treatment protects against acetaminophen-/carbon tetrachloride-induced acute liver injury by inhibiting oxidative stress, inflammation and apoptosis in mice. PMC6334500.
• Diallyl Sulfide and Its Role in Chronic Diseases Prevention. Springer Nature Link. (PubMed PMID 27771923).
• Rahman MA, Midde NM, Wu X, et al. Kinetic characterizations of diallyl sulfide analogs for their novel role as CYP2E1 enzyme inhibitors. Pharmacol Res Perspect. 2017;5(5):e00362. PMC5625166.
• Biological Functions of Diallyl Disulfide, a Garlic-Derived Natural Organic Sulfur Compound. PMC8570849.
• Bioactive Compounds and Biological Functions of Garlic (Allium sativum L.). PMC6678835.
• Allyl Sulfide – an overview. ScienceDirect Topics.
• Acute toxicity of diallyl sulfide derived from Allium sativum (garlic) in mice and its possible mechanisms. ScienceDirect. 2021.
• Historical Perspective on the Use of Garlic. The Journal of Nutrition. 2001.
• Extracts from the history and medical properties of garlic. PMC3249897.
• Garlic as a medicine throughout the ages (Review). Spandidos Publications. 2025.
• Cytochrome P450 enzyme mediated herbal drug interactions (Part 1). PMC4463967.
• Cracking the Sulfur Code: Garlic Bioactive Molecules as Multi-Target Blueprints for Drug Discovery. Pharmaceuticals. 2025. DOI: 10.3390/ph18111766.
• The nutritional value, bioactive availability and functional properties of garlic and its related products during processing. Frontiers in Nutrition. PMC10409574.
• Natural sulfur compounds in mental health and neurological disorders. PMC12014460.
• Revealing the Therapeutic Uses of Garlic (Allium sativum) and Its Potential for Drug Discovery. PMC8739926.
• Garlic (Allium sativum) as a natural antidote or a protective agent against diseases and toxicities: A critical review. ScienceDirect. 2023.
• Warfarin-Durian interaction: A case study bridging clinical outcomes and metabolic profiling through metabolomics. PMC12963912.
• Garlic bioactive substances and their therapeutic applications for improving human health: a comprehensive review. Frontiers in Immunology. 2024.